Pictet & Cie Europe SA purchased a new stake in Zoetis Inc (NYSE:ZTS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 66,000 shares of the company’s stock, valued at approximately $5,623,000.
Several other large investors have also modified their holdings of ZTS. Polen Capital Management LLC grew its position in shares of Zoetis by 125.3% in the first quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock valued at $746,883,000 after purchasing an additional 4,974,081 shares during the last quarter. BlackRock Inc. grew its position in shares of Zoetis by 6.7% in the first quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock valued at $3,429,736,000 after purchasing an additional 2,584,199 shares during the last quarter. Amundi Pioneer Asset Management Inc. grew its position in shares of Zoetis by 319.9% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock valued at $231,187,000 after purchasing an additional 2,109,036 shares during the last quarter. Banque Pictet & Cie SA grew its position in shares of Zoetis by 5,516.1% in the second quarter. Banque Pictet & Cie SA now owns 1,679,617 shares of the company’s stock valued at $143,087,000 after purchasing an additional 1,649,710 shares during the last quarter. Finally, Bank of Montreal Can grew its position in shares of Zoetis by 190.7% in the second quarter. Bank of Montreal Can now owns 1,327,357 shares of the company’s stock valued at $113,078,000 after purchasing an additional 870,807 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors.
In related news, CFO Glenn David sold 16,385 shares of Zoetis stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $92.20, for a total transaction of $1,510,697.00. Following the sale, the chief financial officer now directly owns 29,234 shares of the company’s stock, valued at $2,695,374.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Kristin C. Peck sold 5,000 shares of Zoetis stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $86.22, for a total value of $431,100.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 213,484 shares of company stock worth $19,489,636. 0.35% of the stock is owned by company insiders.
ZTS stock opened at $89.60 on Monday. Zoetis Inc has a twelve month low of $61.08 and a twelve month high of $93.67. The stock has a market cap of $43.17 billion, a P/E ratio of 37.33, a PEG ratio of 1.84 and a beta of 1.02. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. Zoetis had a return on equity of 72.30% and a net margin of 19.95%. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same period last year, the business earned $0.53 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. sell-side analysts predict that Zoetis Inc will post 3.07 earnings per share for the current fiscal year.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Penny Stocks
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.